InSitu Biologics discloses $1.25m convertible note financing
The drug-delivery developer reported $1.25m sold to one investor in an offering targeting $2.5m.
InSitu Biologics disclosed $1.25 million in convertible promissory note financing in a Form D filed on August 10, 2026. The filing reports one investor and a first sale on August 4, with a total offering target of $2.5 million.
The Minnesota company develops a localized drug-delivery platform intended to release therapy near an injection site over several days. Its lead candidate, INSB200, is being developed for post-surgical pain management using a peripheral nerve-block injection.